Peptides, both popular and experimental, have garnered significant attention. Last month, a panel advising the Food and Drug Administration (FDA) held a marathon hearing regarding these drugs. During this session, the panel examined the prospects of seven different peptide therapies, showing support for all but one. However, despite this recommendation, the legal status of these peptides remains unchanged. Compounding pharmacies in the U.S. are still prohibited from producing these substances.
The next steps involve a thorough review by FDA staff and leadership to decide if compounding pharmacies should be allowed to produce the peptides. Dr. Jessica Duncan, Chief Medical Officer at IVIM Health, emphasizes the uncertainty in the timeline for availability. Patients, eager for these therapies, are continuously asking questions.
While there is no certainty, it seems plausible that the FDA might proceed with approval. Historically, the agency adheres to its advisory committees’ recommendations, and demand for these products is substantial. Health Secretary Robert F. Kennedy Jr. has advocated for making them accessible. The formal rulemaking process may take several months to over a year, though Jesse Dresser, legal expert at Frier Levitt, suggests potential for faster approval.
One interim solution might involve placing these peptides on the “Category One list,” allowing pharmacies to start production while waiting for formal rulemaking. This possibility indicates significant pressure, yet Ilisa Bernstein, former FDA official, underscores that data must guide decisions.
Kennedy might use authority reserved for removing dangerous products to fast-track these peptides—a unique approach in a unique scenario, according to legal expert Dresser. Alternatively, the FDA could reject the recommendations, possibly resulting in industry lawsuits. Abha Kundi, an FDA regulatory lawyer, notes the agency’s awareness of these injections’ current portrayal.
The controversy surrounding peptides stems from demand overtaking evidence. Widely promoted for wellness, they are used as “stacks” for muscle growth, injury recovery, and more. None of the seven peptides have been subjected to large-scale human trials, unlike GLP-1 weight-loss drugs.
The gray market for peptides surged after the FDA prohibited compounding pharmacies from their production without concrete human data, risking consumer safety. Dr. Haleem Mohammed, involved in the panel, argues the agency’s meeting presentation lacked comprehensive evidence.
The FDA scientists highlighted the disparity in published human data and complications defining consistent peptide compositions. Bernstein explains that while peptides require evidence for compounding approval, ensuring some safety is essential. Should the FDA support peptides, compounding pharmacies could experience increased demand.
If peptide production gets approved, prescriptions will be necessary. These drugs won’t be found immediately at retailers like CVS or Walgreens but will instead be sourced from compounding pharmacies, needing time to prepare. Scott Brunner from the Alliance for Pharmacy Compounding indicates this transition could take months.
Meanwhile, telehealth companies, medical practices, and spas are already marketing peptides. Yet, traditional doctors may show hesitation in prescribing them due to the lack of standardized guidelines. Dr. Harmeet Narula, an endocrinologist, notes the imbalance between commercial eagerness and clinical verification. Consumers should be aware that current developments do not imply FDA approval for these drugs.